E12: Jamie Rhode on Why 95% of LPs Can Only Achieve a 10% IRR when the Mean Return is 50% IRR

Episode Summary

Executive Summary: Jamie Rode describes a data-driven but non-predictive LP philosophy: use data to improve decision-making, not to pick winners. Veritas builds a diversified seed portfolio to capture venture’s power-law mean return, prioritize compounding over DPI, and reduce volatility through broad network coverage, operational rigor, and selective exposure to life sciences and elite founder ecosystems.

Main Topics: Data-driven LP philosophy (Priority: 5/5): Rode distinguishes between using data to predict winners versus using it to guide investment process, asset allocation, and long-term decision-making. Venture as a power-law asset class (Priority: 5/5): The conversation centers on venture returns being driven by a small number of outliers, making mean returns far more important than medians. Portfolio construction and sampling strategy (Priority: 5/5): Veritas built a seed portfolio to sample roughly 20% of the ecosystem, targeting networks/geographies with consistent outlier production to access the mean return. Compounding over DPI (Priority: 4/5): Rode argues that early exits can destroy long-term value; venture should be held for compounding if the asset continues to grow at high rates. GP diligence, transparency, and operational discipline (Priority: 4/5): The LP evaluates sourcing, LPAs, service providers, reporting timelines, and institutional behavior, emphasizing humility and transparency. Life sciences as a complementary venture strategy (Priority: 4/5): Therapeutics and biotech are presented as a distinct area with higher outlier rates, earlier exits, and downside protection for the overall portfolio. LP ecosystem and anti-groupthink (Priority: 3/5): Rode favors co-investing and diligencing with thoughtful LPs to avoid consensus bias and improve conviction in contrarian choices.

Key Arguments: Data is most useful for guiding investment decisions and building an edge, not for accurately predicting individual winners. Because venture returns are power-law distributed, LPs should optimize for capturing the mean return, not the median return. A diversified seed portfolio can approximate the venture ecosystem better than concentrated ownership-focused strategies, with smoother volatility and similar expected returns. Networks and geographies matter because outlier production is concentrated in specific ecosystems such as California, YC, Stanford, and select talent networks. If a company is clearly a winner, LPs should not reject a small check size solely because it is below typical ownership targets. DPI should not be the primary goal in early-stage venture if the asset is still compounding at a high rate; selling early can materially reduce terminal value. Operational diligence, reporting discipline, and transparent communication are essential because LPs are married to GPs for long periods and need institutional reliability. Life sciences offers a different but attractive opportunity set with more M&A pathways, milestone-based value creation, and downside smoothing for the portfolio. New or emerging managers can be attractive because fund-one networks may access tail opportunities that later funds miss as their sourcing changes. Manager diversity and LP diversity reduce groupthink and can expand access to differentiated deal flow and end-user markets.

Data Points: Typical check size: $500,000 - Used as the benchmark against which a $75,000 investment was framed as small but potentially valuable. Example small check: $75,000 - A GP made a $75K check into a startup that ultimately generated a very large fund return. Portfolio size in example fund: 120 companies - The GP with the $75K check had a 120-company portfolio. Example fund size: $27 million - The fund that produced $30 million of DPI from a small check. DPI generated by one investment: $30 million - Result of the $75K check in the cited fund example. Single-family office generation: 10th generation - Describes Virtus as a long-horizon family office with multi-period investing power. Max drawdown tolerance: 10% to 15% rolling over 3 years - Family risk constraint influencing asset allocation. Annual payout: 1.5% of NAV - A key cash-flow constraint affecting portfolio design. Venture mean return (1990-2017, neutrally weighted): 50% IRR - If a dollar were invested in every U.S. early-stage venture fund over the period. Venture median return (1990-2017): 10% IRR - Illustrates the gap between mean and median in venture. Sampling target of ecosystem: 20% - Monte Carlo analysis suggested sampling 20% of the U.S. seed ecosystem could capture the mean return with high confidence. Underlying startup universe over 3 years: 6,000 startups - Assuming 2,000 startups per year receive a first institutional check. Startup sample count: 1,200 startups - 20% of 6,000 startups, targeted as the needed unique exposure set. Outlier production rate baseline: 1% to 2% - Market data cited for startups becoming outliers in a vintage year. YC outlier production rate: 5% - Cited as a particularly strong network for outlier generation. Early-stage venture CAGR: 25% - Used as the long-term steady-state compounding rate for venture. 12-year compounding multiple: 14.5x - Approximate result of compounding 25% over a typical 12-year fund life. Compounding at year 9.6: 8.5x - Value cited to show how much return is left on the table by exiting earlier. Seed fund deployment window: First 3 years - Preferred pace for GPs to preserve compounding time within a 10-year fund life. Existing seed portfolio: 20 seed-stage funds - Initial portfolio deployed across four vintage years (2017-2020). Underlying portfolio companies: 1,300 - Total startups accessed through the 20 seed funds. Unicorn count: 38 - Reported outcome from the initial seed portfolio. Expected unicorn count: 7 to 18 - Original underwriting expectation versus actual results. Underwritten zero rate: ~33% - Expected one-third of the portfolio to go to zero, but actual results were better. Life sciences outlier rate: 10% - Therapeutics outlier production rate cited as higher than general tech. California exit value: $9 billion - Representative expected exit value cited for California-based companies. Example acquisition structure: $500 million upfront plus milestone payments - Describes typical biotech M&A economics. Fund-one contribution to unicorns: Almost half - Nearly half of the 38 unicorns came from first funds. Re-up rate: 70% - Current proportion of managers the LP re-ups with. Standard fund life: 10 to 12 years - Used in discussion of compounding and deployment pace.

Pivotal Quotes: "I don't think being data-driven necessarily leads to being able to predict winners." — Jamie Rode: Defines his current view of data-driven investing as process-oriented rather than predictive. "The venture portfolio is the compounding machine for the family. We do not look to venture for DPI or liquidity." — Jamie Rode: Explains why Veritas prioritizes long-term compounding over early realization of gains. "Hold your opinions loosely." — Jamie Rode: A core investing philosophy tied to humility, openness to new GPs, and willingness to change views.

Implications: For LPs, the message is to size for power laws, diversify across networks, and evaluate managers on transparency, sourcing, and compounding potential rather than ownership or near-term DPI. For GPs, institutional behavior and faster, focused deployment matter more than branding.